

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ascletis Pharma Inc.**

**歌禮製藥有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1672)**

### **CLARIFICATION ANNOUNCEMENT**

This announcement is published on a voluntary basis by Ascletis Pharma Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”).

The Company pays high attention to the fact that recently certain media reported (the “**Media Reports**”) that Ritonavir and ASC09 fixed-dose combination (active ingredients: ASC09 and Ritonavir) (the “**Products**”) of the Company can be used in the treatment of Wuhan coronavirus, designated 2019-nCoV, was first identified in Wuhan, Hubei Province at the end of 2019.

The Company hereby makes following statements and clarifications to prevent the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company from being misled:

1. The conclusions of the Media Reports are based on the joint research results of Wuhan Institute of Virology, Chinese Academy of Sciences (中國科學院武漢病毒研究所) and the Institute of Toxicology and Drugs, Chinese Academy of Military Medical Sciences (中國人民解放軍軍事醫學科學院毒物藥物研究所). The Company has not participated in the relevant scientific research process and provided relevant drugs for its research.
2. The Products have not yet approved. Ritonavir is an antiviral protease inhibitor used to treat HIV-1 infections. The Company’s Ritonavir generic drug market authorization application (Acceptance No.: CYHS1900609) has been accepted by the National Medicine Products Administration on August 22, 2019. ASC09 fixed-dose combination is a combination of two antiviral protease inhibitors used to treat HIV-1 infection. The Company’s ASC09 fixed-dose combination clinical trial application (Acceptance No.: CXHL1900443) was accepted by the National Medicine Products Administration on December 30, 2019.
3. On January 25, 2020, the Company applied to the National Medical Products Administration (國家藥品監督管理局) and its Drug Evaluation Center to include Ritonavir and ASC09 fixed-dose combination into the national emergency channel. At the time of making this application, the Company was not aware of the joint research results of Wuhan Institute of Virology, Chinese Academy of Sciences and the Institute of Toxicology and Drugs, Chinese Academy of Military Medical Sciences above. As of the date of this announcement, the Company has not yet received relevant confirmation. The Company will actively cooperate with relevant drug regulatory authorities and promptly inform the public of any progress in such applications.

Save as disclosed in this announcement, after having made all reasonable enquiries with the Company, the Board confirms that it is not aware of any other information which must be announced to avoid a false market in the Company's securities or any inside information that needs to be disclosed under the Inside Information Provisions (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited) under Part XIVA of the Securities and Futures Ordinance.

By order of the Board  
**Ascletris Pharma Inc.**  
歌禮製藥有限公司  
**Jinzi Jason WU**  
*Chairman*

Hangzhou, the People's Republic of China,  
January 29, 2020

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; Dr. Ru Rong JI, Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.*